KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Invested Capital (2018 - 2025)

Vir Biotechnology's Invested Capital history spans 8 years, with the latest figure at $765.3 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 34.39% to $765.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $765.3 million, a 34.39% decrease, with the full-year FY2025 number at $765.3 million, down 34.39% from a year prior.
  • Invested Capital hit $765.3 million in Q4 2025 for Vir Biotechnology, down from $796.1 million in the prior quarter.
  • Over the last five years, Invested Capital for VIR hit a ceiling of $2.1 billion in Q3 2022 and a floor of $675.4 million in Q1 2021.
  • Historically, Invested Capital has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2021.
  • Biggest five-year swings in Invested Capital: soared 196.29% in 2022 and later crashed 35.84% in 2025.
  • Tracing VIR's Invested Capital over 5 years: stood at $1.4 billion in 2021, then soared by 45.12% to $2.1 billion in 2022, then fell by 23.47% to $1.6 billion in 2023, then decreased by 26.65% to $1.2 billion in 2024, then tumbled by 34.39% to $765.3 million in 2025.
  • Business Quant data shows Invested Capital for VIR at $765.3 million in Q4 2025, $796.1 million in Q3 2025, and $947.5 million in Q2 2025.